«Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product»: الفرق بين المراجعتين
(أنشأ الصفحة ب' ==الملخص== Drug Testing and Analysis Explore this journal > Drug Testing and Analysis Previous article in issue: Determination of 13C/12C ratios of urinary excre...') |
|||
| سطر 1: | سطر 1: | ||
==الملخص== | ==الملخص== | ||
| − | Drug Testing and Analysis | + | Drug Testing and Analysis Volume 2, Issue 5 May 2010 Pages 225–233 |
| − | + | ||
| − | |||
| − | |||
| − | |||
| − | Volume 2, Issue 5 | ||
| − | May 2010 | ||
| − | Pages 225–233 | ||
| − | |||
Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product | Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product | ||
| − | Authors | + | |
| + | ===Authors=== | ||
Maissa Y. Salem, | Maissa Y. Salem, | ||
Amira M. El-Kosasy, | Amira M. El-Kosasy, | ||
Mohamed G. El-Bardicy, | Mohamed G. El-Bardicy, | ||
Mohamed K. Abd El-Rahman | Mohamed K. Abd El-Rahman | ||
| + | |||
First published: 11 March 2010Full publication history | First published: 11 March 2010Full publication history | ||
| + | |||
DOI: 10.1002/dta.121View/save citation | DOI: 10.1002/dta.121View/save citation | ||
| − | |||
| − | |||
| − | Three sensitive, selective and precise stability-indicating methods for the determination of the anti-Alzheimer's drug, rivastigmine hydrogen tartrate (RIV) in the presence of its alkaline degradation product (major metabolite, NAP 226-90) and in pharmaceutical formulation were developed and validated. The first method is a second derivative (D2) spectrophotometric one, which allows the determination of RIV in the presence of its degradate at 262 nm (corresponding to zero crossing of the degradate) over a concentration range of 50–500 µg/ml with mean percentage recovery 100.18 ± 0.628. The second method is the first derivative of the ratio spectra (DD1) by measuring the peak amplitude at 272 nm over the same concentration range as (D2) spectrophotometric method, with mean percentage recovery 99.97 ± 0.641. The third method is a TLC-densitometric one, where RIV was separated from its degradate on silica gel plates using methanol:butanol:H2O:ammonia (5:4:1:0.01 v:v:v) as a developing system. This method depends on the quantitative densitometric evaluation of thin layer chromatogram of RIV at 263 nm over a concentration range of 20–160 µg/spot, with mean percentage recovery 100.19 ± 1.344. The selectivity of the proposed methods was tested using laboratory-prepared mixtures. The proposed methods have been successfully applied to the analysis of RIV in pharmaceutical dosage forms without interference from other dosage form additives and the results were statistically compared with reference method. Copyright © 2010 John Wiley & Sons, Ltd. | + | ===Abstract=== |
| + | Three sensitive, selective and precise stability-indicating methods for the determination of the anti-Alzheimer's drug, rivastigmine hydrogen tartrate (RIV) in the presence of its alkaline degradation product (major metabolite, NAP 226-90) and in pharmaceutical formulation were developed and validated. The first method is a second derivative (D2) spectrophotometric one, which allows the determination of RIV in the presence of its degradate at 262 nm (corresponding to zero crossing of the degradate) over a concentration range of 50–500 µg/ml with mean percentage recovery 100.18 ± 0.628. The second method is the first derivative of the ratio spectra (DD1) by measuring the peak amplitude at 272 nm over the same concentration range as (D2) spectrophotometric method, with mean percentage recovery 99.97 ± 0.641. The third method is a TLC-densitometric one, where RIV was separated from its degradate on silica gel plates using methanol:butanol:H2O:ammonia (5:4:1:0.01 v:v:v) as a developing system. This method depends on the quantitative densitometric evaluation of thin layer chromatogram of RIV at 263 nm over a concentration range of 20–160 µg/spot, with mean percentage recovery 100.19 ± 1.344. The selectivity of the proposed methods was tested using laboratory-prepared mixtures. The proposed methods have been successfully applied to the analysis of RIV in pharmaceutical dosage forms without interference from other dosage form additives and the results were statistically compared with reference method. | ||
| + | |||
| + | Copyright © 2010 John Wiley & Sons, Ltd. | ||
==رابط== | ==رابط== | ||
مراجعة 09:53، 29 أغسطس 2016
محتويات
الملخص
Drug Testing and Analysis Volume 2, Issue 5 May 2010 Pages 225–233
Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product
Authors
Maissa Y. Salem, Amira M. El-Kosasy, Mohamed G. El-Bardicy, Mohamed K. Abd El-Rahman
First published: 11 March 2010Full publication history
DOI: 10.1002/dta.121View/save citation
Abstract
Three sensitive, selective and precise stability-indicating methods for the determination of the anti-Alzheimer's drug, rivastigmine hydrogen tartrate (RIV) in the presence of its alkaline degradation product (major metabolite, NAP 226-90) and in pharmaceutical formulation were developed and validated. The first method is a second derivative (D2) spectrophotometric one, which allows the determination of RIV in the presence of its degradate at 262 nm (corresponding to zero crossing of the degradate) over a concentration range of 50–500 µg/ml with mean percentage recovery 100.18 ± 0.628. The second method is the first derivative of the ratio spectra (DD1) by measuring the peak amplitude at 272 nm over the same concentration range as (D2) spectrophotometric method, with mean percentage recovery 99.97 ± 0.641. The third method is a TLC-densitometric one, where RIV was separated from its degradate on silica gel plates using methanol:butanol:H2O:ammonia (5:4:1:0.01 v:v:v) as a developing system. This method depends on the quantitative densitometric evaluation of thin layer chromatogram of RIV at 263 nm over a concentration range of 20–160 µg/spot, with mean percentage recovery 100.19 ± 1.344. The selectivity of the proposed methods was tested using laboratory-prepared mixtures. The proposed methods have been successfully applied to the analysis of RIV in pharmaceutical dosage forms without interference from other dosage form additives and the results were statistically compared with reference method.
Copyright © 2010 John Wiley & Sons, Ltd.
